The combination of TBAJ-876, pretomanid and linezolid is being tested in the NC-009 trial for its potential to shorten and improve treatment for both drug-sensitive and drug-resistant tuberculosis (TB). NC-009 evaluates this combination, with different doses of TBAJ-876. TBAJ-876 is a member of the diarylquinoline class, the same class of drugs to which the anti-TB drug, bedaquiline belongs. Bedaquilne is a component of the WHO-recommended six-month BPaL/M regimens for treating drug resistant TB. Previous data suggests that TBAJ-876 can be more efficacious and potent against TB than bedaquiline, with a lower predicted clinical dose and improved safety properties.